Bitter sweet: Fournier’s Gangrene and SGLT2 inhibitors
Abstract
Diabetes mellitus, especially type 2 is becoming the biggest epidemic of the 21st century affecting more than 415 million adults globally and expected to increase to more than 640 million adults by 2040. Patients with diabetes are at high risk for adverse outcomes, notably cardiovascular disease with an increased risk of death. In fact, the 2018 Canadian Diabetes Association (CDA) guidelines have updated the type 2 diabetes management algorithm; if the patient has clinical cardiovascular disease, an antihyperglycemic agent with demonstrated cardiovascular (CV) benefit should be added. There is a growing armamentarium of therapies with Health Canada-approved CV benefit include two from the sodium-glucose co-transporter 2 (SGLT2) inhibitors class namely Canagliflozin and empagliflozin. Despite their many advantages, the Food and Drug Administration (FDA) issued a black box warning for associated necrotizing fasciitis of the perineum in diabetes treated with SGLT2 inhibitors. This case report highlights a case of Fournier’s gangrene (FG) in a male treated with empagliflozin for type 2 diabetes.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.